Natera enrolls first patients in Signatera-guided melanoma trial evaluating early immunotherapy escalation
NTRA•Natera said the first patients have enrolled in a randomized trial testing whether Signatera-guided early immunotherapy escalation improves outcomes for patients with advanced or metastatic melanoma.
1. Trial enrollment begins
Natera reported that the first patients have enrolled in a randomized melanoma trial using its Signatera test to guide treatment escalation. The study will assess whether intensifying immunotherapy earlier improves outcomes compared with continuing standard immunotherapy for patients with persistent molecular residual disease before scans show progression.
